Sanofi Terminates Collaboration with IGM Biosciences, Triggering 80% Workforce Reduction and Strategic Restructuring

May 09, 2025 22:05 CST Updated 22:05

IGM Biosciences

Antibody Drug Developer

Sanofi

Pharmaceutical R&D Developer

Recently, a termination of cooperation in the biopharmaceutical industry has drawn attention. Sanofi suddenly cut off its partnership with IGM Biosciences, a decision that hit hard, plunging IGM Biosciences into difficulties and forcing it to adopt a series of aggressive strategic adjustment measures, including large-scale layoffs.

Partnership Terminates, IGM Biosciences Caught Off Guard

The collaboration between Sanofi and IGM Biosciences was once highly anticipated. Back in March 2022, Sanofi invested $150 million in IGM Biosciences, with both parties planning to jointly develop six IgM antibody agonists—three targeting cancer and three for immunology or inflammation-related targets. At the time, Sanofi also committed to paying up to $940 million in milestone payments per oncology target and up to $1.065 billion per immunology/inflammation target, with the entire collaboration potentially valued at over $6 billion, undoubtedly injecting strong momentum into the development of IGM Biosciences.

However, the collaboration process was not smooth sailing. In April 2024, both parties revised their cooperation agreement, narrowing the scope to only three immunology/inflammation targets. Although IGM Biosciences regained global rights to cancer-related technology, the scale of the partnership had significantly diminished. This year, a notice from Sanofi caught IGM Biosciences off guard. On Monday, Sanofi informed IGM Biosciences of the termination of their collaboration, with the contract officially ending 30 days after the notice was issued. In its filing with the U.S. Securities and Exchange Commission (SEC), IGM Biosciences did not specify the exact reasons for the termination of the collaboration, only stating that both parties believed continuing the partnership was no longer in their mutual interest.

Layoffs and Self-Rescue, Major Adjustment in Company Structure

Losing Sanofi as a strong partner is undoubtedly a heavy blow to IGM Biosciences. In order to maintain operations and save funds, IGM Biosciences announced a series of self-rescue measures while declaring the termination of the partnership. The company decided to significantly reduce its workforce, planning to cut about 80% of the remaining employees. This means that after laying off 100 people in January this year (73% of the total workforce at the time), IGM Biosciences will once again make a large-scale reduction in manpower. If the layoffs are completed, the number of company employees will plummet from 149 at the end of 2024 to only about 7.

Meanwhile, IGM Biosciences has shut down "most" of its laboratories and offices. The company stated in an SEC filing that it will continue to evaluate potential strategic alternatives and restructuring options, but no specific direction has been determined yet. Financially, as of December 31, 2024, IGM Biosciences held $183.8 million in cash, cash equivalents, and marketable securities, which could have sustained the company’s operations for at least a year prior to the termination of the collaboration. However, now facing numerous challenges, these funds will also undergo a severe test.

Industry cooling down, small and medium-sized pharmaceutical companies under widespread pressure

IGM Biosciences' plight is not an isolated case. Recently, numerous small and medium-sized pharmaceutical companies in the biopharmaceuticals industry have been facing severe challenges. On the same day that IGM Biosciences announced layoffs, RallyBio also cut 40% of its workforce due to the poor performance of its leading asset in mid-stage trials. Last week, Pliant Therapeutics similarly laid off approximately 45% of its employees in order to extend its cash runway and support the late-stage development of its drug candidates. These phenomena indicate that, in the current market environment, small and medium-sized pharmaceutical companies are under tremendous pressure in terms of R&D funding and market competition, and any minor setback could significantly impact their survival and growth.

The termination of the collaboration between Sanofi and IGM Biosciences not only impacted the development trajectories of both companies but also served as a wake-up call for the entire biopharmaceutical industry. Whether IGM Biosciences can find new directions for growth amid challenges, and how small and medium-sized pharmaceutical companies in the industry should respond to similar crises, remains worth continued attention.

Reference Source:https://www.biospace.com/business/sanofi-cuts-off-antibody-partner-forcing-80-headcount-reduction-at-igm

Scan the WeChat QR code, add the editor of the Biologics Circle, and those who meet the requirements can join.
Biological Products WeChat Group!
Please indicate: Name + Research Direction!

Edition
Authority
Sound
Ming

All reproduced articles in this official account are intended to convey more information, with the source and author clearly indicated. Media or individuals who do not wish to be reproduced can contact us (cbplib@163.com), and we will immediately delete the content. All articles represent the views of the author and not this site.